DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neos Therapeutics, Inc. (NASDAQ: NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (“XR”) product candidates for ...
Dec 20 (Reuters) - Drug developer Neos Therapeutics Inc said on Tuesday it resubmitted the marketing application for its attention deficit/hyperactivity disorder (ADHD) drug to the U.S. Food and Drug ...
Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) - Neos Therapeutics Inc said the U.S. Food and Drug Administration identified deficiencies that preclude discussion of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results